VXCO-100

BIOLOGICAL2 trials

Sponsors

Vaccine Company, Inc.

Conditions

SARS-CoVSARS-CoV-2

Phase 1

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

CompletedNCT05870839

Vaccine Company, Inc.SARS-CoV, SARS-CoV-2

Start: 2023-05-11End: 2024-04-10Updated: 2024-12-10

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

CompletedNCT05938075

Vaccine Company, Inc.SARS-CoV, SARS-CoV-2

Start: 2023-08-04End: 2024-07-25Updated: 2024-12-10